Applied Filters
European Commission proposes ‘single market’ for meds
Proposals include new regulatory protection periods for innovative drugs | Changes are aimed at improving patient access to therapeutics and boosting the EU pharma industry.
Cipla loses fightback over diarrhoea antibiotic
Judge rejects notion that tribunal acted unfairly in royalties dispute with Salix | Indian firm wanted payments on sales of antibiotic | Appeal brought under act with ‘high hurdle to surmount’.
EPO Enlarged Board of Appeal issues G 2/21 decision
Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.
Oxford University startup ordered to pay royalties
‘Rare’ case included ‘campaigning element’ says judge | Ex-student sought clarification on royalties from university | 651-paragraph ruling required Oxford Uni to justify its IP policies.
Amgen seals $28m deal for biotech
Two rivals withdrew from acquisition process| Agreement provides access to blockbuster medicines | Janssen Global Services | Sanofi.
Voluntary licensing opens up HIV treatment to 100 countries
Medicines Patent Pool deals have given 20 million people access to HIV treatment | Full list of sub-licensees.
Pharma owners warned of Brexit effect on TMs
Large market for parallel or ‘grey’ imports of pharmaceuticals due to pricing differences in various countries | Govt consultation respondents unhappy with ‘lack of EU reciprocity’| Mewburn Ellis.
Patent firms unveil joint UPC ‘powerhouse’
Firms aim to form a UPC litigation alliance | New court has significant implications for life sciences | UPC faces calls for delay over concerns regarding its case management system.
In conversation with...Beatriz San Martin, Arnold & Porter
The scientist-turned IP specialist chats to LSIPR about why she ‘loves’ the IP sector, her views on policy and funding in science and research, and the cases she’s most proud of.
Teva breached antitrust rules over Copaxone, says EU
European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be found to have infringed Article 102 of TFEU.
